AstraZeneca Held Talks with Bristol Myers Squibb on $400B Deal
Pharmaceutical giant AstraZeneca reportedly held talks with rival Bristol Myers Squibb concerning a potential merger valued at $400 billion, according to a source reported by Reuters.
Pharmaceutical giant AstraZeneca held talks with rival Bristol Myers Squibb regarding a potential $400 billion megadeal, according to a source familiar with the matter cited by Reuters.
The preliminary discussions between the two pharmaceutical titans involved prospective business combination strategies. The reported $400 billion valuation underscores the massive scale of the potential healthcare transaction.
Neither company has officially confirmed the status or specifics of the reported negotiations. According to the source, it remains unclear whether the conversations are ongoing or if formal terms were proposed.
A potential merger between AstraZeneca and Bristol Myers Squibb would mark one of the largest corporate transactions in global financial and pharmaceutical history.
Reuters reported the confidential discussions based on an undisclosed source, with neither company issuing official public commentary on the matter.
Source attribution
- cnbc.com
- ft.com
- cnbc.com
- news.google.com
Original source links
- cnbc.com: Original source
- ft.com: Original source
- cnbc.com: Original source
- news.google.com: Original source
About this story
InstaBriefs summary based on the sources listed above — not a copy of the original article.
Tags
AstraZeneca · Bristol Myers Squibb · Pharmaceuticals · Mergers and Acquisitions · Business
Every story is attributed and linked to its original source. Editorial standards
Related briefs
Big Pharma Scale: How Balance Sheets Drive Blockbuster Drug Bets
Pharmaceutical leaders AstraZeneca and Bristol-Myers highlight how corporate scale and enlarged balance sheets allow major drugmakers to make larger investments in prospective blockbuster medications.
Questions Mount Over Strategic Focus of AstraZeneca and BMS
Industry analysis highlights key strategic questions surrounding AstraZeneca and BMS, including focus areas in oncology, cardiology, patent-cliff avoidance, and U.S. market expansion.
AstraZeneca Shares Fall Sharply on Mega-Merger Rumors
Shares of AstraZeneca fell sharply following market speculation regarding a potential mega-merger. Industry reports linked the stock decline to unconfirmed rumors of a deal involving Bristol Myers Squibb.
Damietta Governor Chairs Meeting to Boost Factory Safety Standards
Dr. Hossam El-Din Fawzy, Governor of Damietta, led an expanded meeting to evaluate and enhance safety mechanisms in factories located within Damietta City's industrial zone.
Telecom Egypt Launches New Summer Promotional Campaign for Customers
Telecom Egypt (WE) has introduced its new summer campaign designed to provide customers with added value, exclusive offers, and tailored benefits.
Egypt Media Council Explores Investment Cooperation with Zee Entertainment
Engineer Khaled Abdel Aziz, head of Egypt's Supreme Council for Media Regulation, received a delegation from Zee Entertainment Middle East to discuss media investment opportunities and strategic cooperation.